CytoDyn Inc (OTCMKTS:CYDY) is a micro-cap name that’s clearly begun to spur some interest among players in the marketplace in recent days as shares bounce up off recent lows. The company recently announced that Nader Pourhassan, Ph.D., President and CEO, will present at the LD Micro Main Event on December 7. The conference is being held at the Luxe Sunset Hotel in Los Angeles. The stock looks like it may be running into that event and the market may be starting to suggest that an important announcement could be in the making.
In any case, the action has been mostly positive here since the stock’s collapse in September on a $10 million direct offering. Traders will note 14% tacked on to share pricing for the stock in the past month. What’s more, the name has seen interest climb, with an increase in recent trading volume of 13% above its longer-run average levels.
CytoDyn Inc (OTCMKTS:CYDY) trumpets itself as a biotechnology company that focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection.
The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry.
Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5.
Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. CytoDyn Inc intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where CCR5 and its ligand CCL5 may be involved.
CytoDyn Inc. is based in Vancouver, Washington.
Find out when $CYDY stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
According to the company’s press materials, “The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.”
If there is going to be any meat on the bone of the company’s presentation on December 7, it will likely have to do with this ongoing Phase 2b extension study with PRO 140 as a monotherapy for the treatment of patients with HIV. The company recently announced that the study was accepted for a poster presentation, as well as a “themed discussion” at the Conference on Retroviruses and Opportunistic Infections (CROI), which is being held in Seattle from February 13 to 16, 2017. So, this is where the emphasis and likely the good news will be seated.
The abstract upcoming in February, “PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update,” was selected for a Themed Discussion Presentation by the CROI Program Committee. This presentation will include four or five abstracts merged into a special theme-oriented, hour-long discussion featuring a brief summary of noteworthy results, conclusions and discussion points.
Apparently, according to recent press, the presentations will be followed by an interactive discussion that synthesizes the relevant information of the abstracts, covers key points of agreement and controversy and draws comparisons to related work in the scientific field.
Now commanding a market cap of $100.8M, CYDY has a significant war chest ($4.44M) of cash on the books, alongside total assets just under $9.3M, which stands against very little total accumulated short and long-term debt, but a mounting $3 million-plus in currently reported accounts payable. Nonetheless, for a pre-revenue biotech, this is an astoundingly good balance sheet as far as we can see. Hence, we will gladly follow this story as it evolves from here. For continuing coverage on shares of $CYDY stock, as well as our other hot stock picks, sign up for our free newsletter now and get our next hot stock pick!
